Skip to Main Content
Contribute Try STAT+ Today

New versions of Bluebird Bio’s gene therapy for inherited blood disorders yielded significant benefits for patients, according to updated results from ongoing clinical trials released Friday.

But whether those benefits will endure for the patients with those conditions, beta-thalassemia and sickle cell disease, remains an open question, even as the Cambridge-based biotech prepares to submit for its first marketing approval in Europe by the end of the year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • So the Trump FDA is refusing and resisting putting this encouraging new treatment and possible cure to sickle cell disease on fast track review and approval because and why? Obvious answer with Trump & Pence and McConnell and Ryan…..what demographic is impacted by sickle cell disease? African-Americans!

  • PLEASE Let Me Know if you have a Clinical trial for Rheumatoid and Osteo Arthritis .

Comments are closed.